Pneumonia viral – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:15:36 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Pneumonia viral – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of inhaled interferon beta-1a (SNG001) for treatment of patients with viral lower respiratory tract infections who require mechanical ventilation https://clinicaltrials.eu/trial/study-of-inhaled-interferon-beta-1a-sng001-for-treatment-of-patients-with-viral-lower-respiratory-tract-infections-who-require-mechanical-ventilation/ Wed, 27 May 2026 04:04:48 +0000 https://clinicaltrials.eu/trial/study-of-inhaled-interferon-beta-1a-sng001-for-treatment-of-patients-with-viral-lower-respiratory-tract-infections-who-require-mechanical-ventilation/ This study focuses on treating patients with lower respiratory tract viral infections who require breathing support through a ventilator. The study will test a medication called SNG001, which contains interferon beta-1a and is given through inhalation using a nebulizer (a device that turns liquid medicine into a fine mist that can be breathed in). The study will include patients who have various respiratory viruses, including influenza, respiratory syncytial virus, rhinovirus, adenovirus, parainfluenza, human metapneumovirus, and coronaviruses.

The purpose of this research is to determine if SNG001 is safe and effective for treating patients on ventilators who have viral respiratory infections. The study is divided into two parts – the first part will look at the safety of the treatment, while the second part will compare SNG001 to placebo to see how well it works. Patients will receive either SNG001 or placebo through a nebulizer while they are on a ventilator.

During the study, doctors will monitor patients’ recovery, including how long they need to stay in the intensive care unit, how long they need ventilator support, and whether the treatment helps them recover from their viral infection. The treatment period will last up to 14 days, and patients will be monitored for up to 28 days to assess their recovery.

]]> Study of vitamin D3 (cholecalciferol) as additional treatment for elderly patients with pneumonia or sepsis due to infection https://clinicaltrials.eu/trial/study-of-vitamin-d3-cholecalciferol-as-additional-treatment-for-elderly-patients-with-pneumonia-or-sepsis-due-to-infection/ Wed, 29 Apr 2026 15:06:23 +0000 https://clinicaltrials.eu/trial/study-of-vitamin-d3-cholecalciferol-as-additional-treatment-for-elderly-patients-with-pneumonia-or-sepsis-due-to-infection/ This clinical trial investigates the effects of high-dose vitamin D3 (cholecalciferol) in elderly patients who are hospitalized with either pneumonia or sepsis. Pneumonia is a lung infection that can be seen on chest x-rays, while sepsis is a serious condition where the body has an extreme response to an infection that can be life-threatening.

The study tests whether giving additional vitamin D3 along with standard treatment can help patients leave the hospital sooner or reduce inflammation in the body. Participants will receive either vitamin D3 solution (DIBASE) or placebo in the form of refined olive oil. The treatment will be given by mouth and can last up to 12 months.

The research focuses on measuring how well patients recover during their hospital stay, including how quickly they can be discharged and whether they need intensive care. The study will also track changes in substances in the blood that show inflammation levels, particularly proteins called IL-6 and C-reactive protein. Patients will be monitored for up to 90 days to assess their recovery and any effects of the treatment.

]]>